Last Week in GER Research: Meituan, China Tower, Haidilao, Qutoutiao, Hua Med., Chunlai, and Cootek
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we assess Meituan's latest results ahead of its...
328 Views
ECM Weekly (8 September 2018) - Qutoutiao, Viomi, 111 Inc., Meituan, Haidilao
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
470 Views
Last Week in GER Research: Meituan-Dianping, Nio, Gangfeng Lithium, Pinduoduo and 111 Inc
Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a more palatable...
337 Views
Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome
Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...
792 Views
Hua Medicine (华领医药) IPO: Little Upside to Fair Value
Hua Medicine launched the institutional book building today and intends to raise USD 111 to USD 124 million, with an implied market capitalization...
528 Views